Twin Peaks Wealth Advisors’s Vaxcyte PCVX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14	Closed	-$814	–	1615
2026 Q1	$814	Buy	+14	New	+$760	﹤0.01%	1944

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Twin Peaks Wealth Advisors's PCVX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 14 shares — an estimated $814 sold.

Twin Peaks Wealth Advisors first reported a position in PCVX in Q1 2026 and held it in 1 quarter. The position peaked at $814 in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 14 Vaxcyte shares in Q2 2026, an estimated $814.
Twin Peaks Wealth Advisors first reported a position in Vaxcyte in Q1 2026 and held it in 1 quarter.
Twin Peaks Wealth Advisors's Vaxcyte position peaked at $814 in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.